Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects

NCT01154114 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Atherosclerosis

Interventions

DRUG: darapladib

Sponsor

GlaxoSmithKline